The US Food and Drug Administration (FDA) has granted approval to Epigenomics’ blood-based colorectal cancer screening test, Epi proColon, making it the first and only FDA-approved colorectal cancer screening test.

Under a joint commercialisation agreement with the company’s strategic partner Polymedco, the screening test will be introduced in the US.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

Epigenomics CEO and CFO Dr Thomas Taapken said: "While colorectal cancer remains the second-leading cause of cancer death in the US, one out of three eligible Americans still does not undergo colorectal cancer screening.

"Given the significant benefits for patients, healthcare professionals and payors, Epi proColon could help to meet the objective of 80% screening compliance of the eligible US population."

"Given the significant benefits for patients, healthcare professionals and payors, Epi proColon could help to meet the objective of 80% screening compliance of the eligible US population as pursued by US guideline bodies such as the American Cancer Society."

Epi proColon is an in-vitro polymerase chain reaction (PCR) assay to detect the septin9 gene methylation in DNA isolated from the patient’s plasma.

This can serve as an alternative for average-risk patients who do not choose to be administered with guideline-recommended methods such as a colonoscopy and stool-based fecal immunochemical tests (FIT).

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The test is done only on a blood sample to be drawn from the patient during routine healthcare provider visits with no added dietary restrictions or alterations in medication required for the test.

The sample will be analysed at a local or regional diagnostic laboratory.

After securing the FDA approval, the company will begin a post-approval study to exhibit the long-term benefit of blood-based colorectal cancer screening using Epi proColon.